目的 探討腎炎康復片聯(lián)合甘精胰島素注射液治療糖尿病腎病的臨床療效。方法 選取2015年3月—2016年9月宜昌市第二人民醫(yī)院收治的糖尿病腎病患者74例作為研究對象，按照隨機數(shù)字表法分為對照組和治療組，每組各37例。對照組每晚睡前皮下注射甘精胰島素注射液，初始劑量8 IU，每3天調整1次，每次調整范圍在2～4 IU。治療組在對照組基礎上口服腎炎康復片，5片/次，3次/d。兩組患者均連續(xù)治療12周。觀察兩組的臨床療效，比較兩組的血糖、腎功能、炎癥反應因子水平的變化。結果 治療后，對照組、治療組的總有效率分別為64.86%、89.19%，兩組患者臨床總有效率比較差異具有統(tǒng)計學意義（P< 0.05）。治療后，兩組患者肌酐（Scr）、24 h尿蛋白定量（Upro）、空腹血糖（FBG）、餐后2 h血糖（2 h PG）均顯著降低，同組治療前后比較差異具有統(tǒng)計學意義（P< 0.05）；且治療組Scr、Upro顯著低于對照組，兩組比較差異具有統(tǒng)計學意義（P< 0.05）。治療后，兩組腫瘤壞死因子α（TNF-α）、C反應蛋白（CRP）、轉化生長因子（TGF-β1）均顯著降低，同組治療前后比較差異具有統(tǒng)計學意義（P< 0.05）；且治療組各指標明顯低于對照組，兩組比較差異具有統(tǒng)計學意義（P< 0.05）。結論 腎炎康復片聯(lián)合甘精胰島素注射液治療糖尿病腎病具有較好的臨床療效，能夠改善腎功能，減輕炎癥反應，具有一定的臨床推廣應用價值。

Objective To study the clinical effect of Shenyan Kangfu Tablets combined with Insulin Glargine Injection in treatment of diabetic nephropathy. Methods Patients (74 cases) with diabetic nephropathy in Yichang Second People's Hospital from March 2015 to September 2016 were randomly divided into control and treatment groups according to random number table method, and each group had 37 cases. Patients in the control group were sc administered with Insulin Glargine Injection before bedtime, with an initial dose of 8 IU, adjusted once every 3 d, with a range of 2-4 IU each time. Patients in the treatment group were po administered with Shenyan Kangfu Tablets on the basis of the control group, 5 tablets/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, and blood glucose, renal function, and inflammatory response factor level in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 64.86% and 89.19%, respectively, and there was difference between two groups (P < 0.05). After treatment, Scr, Upro, FBG, and 2 h PG in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And Scr and Upro in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, TNF-α, CRP, TGF-β1 in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Shenyan Kangfu Tablets combined with Insulin Glargine Injection has clinical curative effect in treatment of diabetic nephropathy, can significantly improve renal function, and reduce inflammation response, which has a certain clinical application value.